Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14256301 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL13935383 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL5278688 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL5820808 | 0.98 | ALDH1A1 (0.47) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL16556737 | 0.95 | ALDH1A1 (0.45) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL5817823 | 0.93 | SMN1; SMN2 (0.47) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL29581677 | 0.91 | TSHR (0.39) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL5275198 | 0.90 | SMN1; SMN2 (0.44) | ALDH1A1TDP1SMN1; SMN2MEN1THRB | |
| SCHEMBL11759538 | 0.89 | TSHR (0.40) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL5822587 | 0.88 | SMN1; SMN2 (0.36) | ALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | DIC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | DIC CORPORATION (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20090041945-A1 | ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20080180501-A1 | Actinic Ray Curable Composition, Actinic Ray Curable Ink, Image Forming Method Utilizing the Same, Ink-Jet Recording Apparatus and Epoxy Compound | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-7390840-B2 | Active ray curable composition, active ray curable ink, image forming method and inkjet recording apparatus utilizing the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20080107821-A1 | Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080180501-A1 | Actinic Ray Curable Composition, Actinic Ray Curable Ink, Image Forming Method Utilizing the Same, Ink-Jet Recording Apparatus and Epoxy Compound | ROCK1, MACF1, ACTN1 | ALDH1A1 2444/4885TDP1 1632/4885SMN1; SMN2 2311/4885 |
| US-20080107821-A1 | Polymerizable Actinic Radiation Curable Composition, Polymerization Method, Actinic Radiation Curable Ink and Image Formation Method, and Ink Jet Recording Apparatus and Epoxy Compound | CBR3, CBR1, CNR1 | ALDH1A1 3110/4885TDP1 3529/4885SMN1; SMN2 2056/4885 |
| US-20170362508-A1 | POLYMERIZABLE COMPOUND AND OPTICALLY ANISOTROPIC BODY | PBDC1, RCC1, PUF60 | ALDH1A1 2864/4885TDP1 859/4885SMN1; SMN2 2476/4885 |
| US-20180022716-A1 | POLYMERIZABLE COMPOUND AND OPTICAL ISOMER | SMC4, MAP1LC3C, ZW10 | ALDH1A1 3195/4885TDP1 2599/4885SMN1; SMN2 2546/4885 |
| US-20090041945-A1 | ACTIVE RAY CURABLE COMPOSITION, POLYMERIZATION METHOD, ACTIVE RAY CURABLE INK, IMAGE FORMING METHOD, AND INK-JET RECORDING APPARATUS | RIF1, NAP1L4, NAP1L1 | ALDH1A1 2785/4885TDP1 676/4885SMN1; SMN2 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.